BioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 04/17/24
BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ETPRNewsWire • 04/10/24
New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics MeetingPRNewsWire • 03/12/24
Here's What Key Metrics Tell Us About BioMarin (BMRN) Q4 EarningsZacks Investment Research • 02/23/24
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024PRNewsWire • 02/22/24
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & MoreZacks Investment Research • 02/21/24
Seeking Clues to BioMarin (BMRN) Q4 Earnings? A Peek Into Wall Street Projections for Key MetricsZacks Investment Research • 02/19/24
BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ETPRNewsWire • 02/08/24
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) CongressPRNewsWire • 02/06/24
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Growth Stock: Should You Buy?Zacks Investment Research • 01/15/24
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 NamesInvestorPlace • 01/10/24
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CAPRNewsWire • 01/03/24